244 related articles for article (PubMed ID: 30467591)
1. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
Yin O; Xiong Y; Endo S; Yoshihara K; Garimella T; AbuTarif M; Wada R; LaCreta F
Clin Pharmacol Ther; 2021 May; 109(5):1314-1325. PubMed ID: 33118153
[TBL] [Abstract][Full Text] [Related]
6. Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
Liu SN; Lu T; Jin JY; Li C; Girish S; Melnikov F; Badovinac Crnjevic T; Machackova Z; Restuccia E; Kirschbrown WP
J Clin Pharmacol; 2021 Aug; 61(8):1096-1105. PubMed ID: 33719071
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
Li C; Agarwal P; Gibiansky E; Jin JY; Dent S; Gonçalves A; Nijem I; Strasak A; Harle-Yge ML; Chernyukhin N; LoRusso P; Girish S
Clin Pharmacokinet; 2017 Sep; 56(9):1069-1080. PubMed ID: 27995530
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
[TBL] [Abstract][Full Text] [Related]
9. Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.
Le Tilly O; Azzopardi N; Bonneau C; Desvignes C; Oberkampf F; Ezzalfani M; Ternant D; Turbiez I; Gutierrez M; Paintaud G
Clin Pharmacol Ther; 2021 Jul; 110(1):210-219. PubMed ID: 33547646
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
Heo YA; Syed YY
Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
[TBL] [Abstract][Full Text] [Related]
14. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
Xiang H; Liu L; Gao Y; Ahene A; Collins H
Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A
Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
17. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Cosson VF; Ng VW; Lehle M; Lum BL
Cancer Chemother Pharmacol; 2014 Apr; 73(4):737-47. PubMed ID: 24519752
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
